Staar Surgical Company (STAA)
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical Q1 Earnings Call Highlights
STAAR Surgical NASDAQ: STAA said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls following a difficult 2025.
Compared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.52 per share a year ago.
Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surging Earnings Estimates Signal Upside for Staar Surgical (STAA) Stock
Staar Surgical (STAA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Insider Buying: STAAR Surgical (NASDAQ:STAA) Director Purchases $5,881,076.37 in Stock
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 316,017 shares of the business's stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director owned
Insider Buying: STAAR Surgical (NASDAQ:STAA) Director Purchases $5,425,707.84 in Stock
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 299,432 shares of the business's stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $18.12 per share, with a total value of $5,425,707.84. Following the completion of the purchase, the director owned 15,807,825 shares
STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years
STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.
Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
